Market capitalization | $416.10m |
Enterprise Value | $260.80m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 2.37 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-93.09m |
Free Cash Flow (TTM) Free Cash Flow | $-74.51m |
Cash position | $174.38m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
7 Analysts have issued a Aura Biosciences forecast:
7 Analysts have issued a Aura Biosciences forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -1.26 -1.26 |
7%
7%
|
|
EBITDA | -92 -92 |
20%
20%
|
EBIT (Operating Income) EBIT | -93 -93 |
20%
20%
|
Net Profit | -83 -83 |
17%
17%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.
Head office | United States |
CEO | Elisabet Pinos |
Employees | 89 |
Founded | 2007 |
Website | www.aurabiosciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.